Back

Survival in HFpEF vs HFrEF patients after beta-blocker titration: New insights from the CIBIS-ELD trial

23 May 2016 (09:36 - 09:42)
Organised by:
Congress Presentation Part of: Rapid Fire 3 - Chronic heart failure management Chronic nursing care HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor Hans-Dirk Duengen

Scirent - Clinical Research and Science, Berlin (Germany)

13 More presentations in this session

Presentation thumbnail
Morbidity, mortality, and cost impact of stage b and stage c heart failure: comparative analysis to underline the clinical and economic need for heart failure prevention strategy.
Doctor S. James (Castlebar, IE)
Abstract Slides
Presentation thumbnail
Effects of 5 years treatment with nebivolol, carvedilol and bisoprolol in heart failure patients
Doctor G. Marazzi (Rome, IT)
Abstract
Presentation thumbnail
MTP-131, a cardiolipin-targeting peptide, improves mitochondrial activity in the failing human heart
Doctor B. Stauffer (Aurora, US)
Abstract Slides
Presentation thumbnail
Is the cohort of paradigm-hf representative of the real world population of patients with systolic heart failure?
Doctor G. Rocha Rodrigues (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Evidence-based medications in multi-ethnic Asian patients with heart failure are associated with better outcomes in spite of lower doses
Doctor T. Teng (Singapore, SG)
Abstract Slides

Access the full session

Session thumbnail
Rapid Fire 3 - Chronic heart failure management

The Event

Event poster

HEART FAILURE 2016

23 May 2016 09:36 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources